UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical trial design during and beyond the pandemic: the I-SPY COVID trial

Nature medicine, 2022-01, Vol.28 (1), p.9-11

2022

Volltextzugriff (PDF)

Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort

Urology (Ridgewood, N.J.), 2017-09, Vol.107, p.67-75

2017

Volltextzugriff (PDF)

Using Radiomics in Cancer Management

JCO precision oncology, 2024-05, Vol.8 (8), p.e2400155

2024

Volltextzugriff (PDF)

Human In vivo Dose-Response to Controlled, Low-Dose Low Linear Energy Transfer Ionizing Radiation Exposure

Clinical cancer research, 2006-06, Vol.12 (12), p.3723-3729

2006

Volltextzugriff (PDF)

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease

European urology, 2018-01, Vol.73 (1), p.129-138

2018

Volltextzugriff (PDF)

MP35-07 THE 17-GENE RT-PCR PROSTATE ASSAY: CLINICAL EXPERIENCE IN 29,000 PATIENTS WITH CLINICALLY LOW-RISK PROSTATE CANCER

The Journal of urology, 2018-04, Vol.199 (4), p.e449-e449

2018

Volltextzugriff (PDF)

A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility

Urology (Ridgewood, N.J.), 2019-04, Vol.126, p.76-82

2019

Volltextzugriff (PDF)

17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1549-1557

2020

Volltextzugriff (PDF)

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.219-219

2021

Volltextzugriff (PDF)

Assessing probe-specific dye and slide biases in two-color microarray data

BMC bioinformatics, 2008-07, Vol.9 (1), p.314-314, Article 314

2008

Volltextzugriff (PDF)

The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer

Urology (Ridgewood, N.J.), 2020-09, Vol.143, p.103-111

2020

Volltextzugriff (PDF)

Improving Collection and Analysis of Overall Survival Data

Clinical cancer research, 2024-09, Vol.30 (18), p.3974-3982

2024

Volltextzugriff (PDF)

Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P5-P5-13-12

2022

Volltextzugriff (PDF)

MP35-14 A 17-GENE ASSAY DRIVES HIGH ACTIVE SURVEILLANCE PERSISTENCE IN CLINICALLY LOW-RISK PROSTATE CANCER: 1 YEAR RESULTS FROM A 1,200 PATIENT PROSPECTIVE OBSERVATIONAL TRIAL

The Journal of urology, 2018-04, Vol.199 (4), p.e452-e452

2018

Volltextzugriff (PDF)

MP67-10 A 17-GENE GENOMIC ASSAY AS A PREDICTOR OF OUTCOMES IN AFRICAN AMERICANS WITH PROSTATE CANCER

The Journal of urology, 2020-04, Vol.203 (Supplement 4)

2020

Volltextzugriff (PDF)

The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.514-514

2022

Volltextzugriff (PDF)

Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer

The Journal of urology, 2021-04, Vol.205 (4), p.1047-1054

2021

Volltextzugriff (PDF)

Abstract PD10-07: Chemokine12 (CK12) tertiary lymphoid gene expression signature as a predictor of response in 3 immunotherapy arms of the neoadjuvant ISPY 2 TRIAL - pembrolizumab with and without SD101, and durvalumab combined with olaparib - and in 9 other arms of the trial including platinum-based and dual-anti-HER2 therapies

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD10-07-PD10-07

2022

Volltextzugriff (PDF)

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT1-10-02-OT1-10-02

2022

Volltextzugriff (PDF)

Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy

Urologic oncology, 2022-03, Vol.40 (3), p.104.e1-104.e7

2022

Volltextzugriff (PDF)

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD8-07-PD8-07

2022

Volltextzugriff (PDF)

Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

Critical care (London, England), 2024-02, Vol.28 (1), p.56, Article 56

2024

Volltextzugriff (PDF)

Evaluation of the contribution of individual gene groups to a 17-gene prognostic prostate cancer signature

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5060-5060

2015

Volltextzugriff (PDF)

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations

BMJ open, 2022-06, Vol.12 (6), p.e060664-e060664

2022

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(83)

Publikationsform

Sprache

Englisch
(107)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Technology
(35)
Life Sciences & Biomedicine
(33)
Materials Science
(26)
Humans
(24)
Materials Science, Multidisciplinary
(15)
Physical Sciences
(13)
Male
(12)
Engineering
(11)
Materials Science, Ceramics
(11)
Chemistry
(10)
Middle Aged
(10)
Aged
(9)
Oncology
(9)
Biochemistry & Molecular Biology
(8)
Female
(8)
Adult
(7)
Urology & Nephrology
(7)
Chemistry, Multidisciplinary
(6)
Prostatic Neoplasms - Genetics
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Clinical trial design during and beyond the pandemic: the I-SPY COVID trial

Use of a 17-gene prognostic assay in contemporary urologic practice: results of an interim analysis in an observational cohort

Using Radiomics in Cancer Management

Human In vivo Dose-Response to Controlled, Low-Dose Low Linear Energy Transfer Ionizing Radiation Exposure

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease

MP35-07 THE 17-GENE RT-PCR PROSTATE ASSAY: CLINICAL EXPERIENCE IN 29,000 PATIENTS WITH CLINICALLY LOW-RISK PROSTATE CANCER

A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility

17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort

Adverse pathology as a predictor of distant metastasis and prostate cancer mortality with 20-year follow up

Assessing probe-specific dye and slide biases in two-color microarray data

The 17-Gene Genomic Prostate Score Test as a Predictor of Outcomes in Men with Unfavorable Intermediate Risk Prostate Cancer

Improving Collection and Analysis of Overall Survival Data

Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL

MP35-14 A 17-GENE ASSAY DRIVES HIGH ACTIVE SURVEILLANCE PERSISTENCE IN CLINICALLY LOW-RISK PROSTATE CANCER: 1 YEAR RESULTS FROM A 1,200 PATIENT PROSPECTIVE OBSERVATIONAL TRIAL

MP67-10 A 17-GENE GENOMIC ASSAY AS A PREDICTOR OF OUTCOMES IN AFRICAN AMERICANS WITH PROSTATE CANCER

The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2

Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in African American and Caucasian American Men with Clinically Localized Prostate Cancer

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast cancer

Validating the association of adverse pathology with distant metastasis and prostate cancer mortality 20-years after radical prostatectomy

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

Evaluation of the contribution of individual gene groups to a 17-gene prognostic prostate cancer signature

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations

Suchergebnisse filtern